Use of glatiramer acetate between 2010–2015: effectiveness, safety and reasons to start GA as first or second line treatment in Swiss multiple sclerosis patients

Background Glatiramer acetate (GA) is one of the first therapies approved for multiple sclerosis (MS). We prospectively included and monitored drug-naïve and pre-treated MS patients who had been prescribed GA for 1 year, to investigate reasons for GA prescription, its effectiveness and safety in rea...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	BMC neurology Jg. 19; H. 1; S. 159 - 9
Hauptverfasser:	Zecca, Chiara, Disanto, Giulio, Sacco, Rosaria, Riccitelli, Gianna C., Gobbi, Claudio
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	London BioMed Central 12.07.2019 BioMed Central Ltd BMC
Schlagworte:	Biological response modifiers CIS Comorbidity Demyelinating diseases Dosage and administration Drug approval Drug therapy Glatiramer acetate Interferon Medical records Medicine Medicine & Public Health Multiple sclerosis Neurochemistry Neurology Neurosurgery Patient monitoring equipment Patient outcomes Prescription writing Relapsing remitting Research Article Therapy Switzerland Glatiramer acetate Relapsing remitting Therapy Multiple sclerosis GA CIS
ISSN:	1471-2377, 1471-2377
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!